Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. - Wikidata - awgldk - TriplyDB

Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

http://www.wikidata.org/entity/Q33930081

about

Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses Molecular imaging of oncolytic viral therapy Trial Watch:: Oncolytic viruses for cancer therapy Measles to the Rescue: A Review of Oncolytic Measles Virus IQGAP1 suppresses TβRII-mediated myofibroblastic activation and metastatic growth in liver Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.Viral oncolysis - can insights from measles be transferred to canine distemper virus?VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.Remission of disseminated cancer after systemic oncolytic virotherapy Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.Attenuated oncolytic measles virus strains as cancer therapeutics A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.Enhancing cytokine-induced killer cell therapy of multiple myeloma.Oncolytic measles virus strains as novel anticancer agents.A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity.The Na+/I- symporter (NIS): mechanism and medical impact.Use of attenuated paramyxoviruses for cancer therapy.Recent advances in oncolytic virus design.Oncolytic virotherapy Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Antitumor Virotherapy by Attenuated Measles Virus (MV).Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Potential and clinical translation of oncolytic measles viruses.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Cell carriers for oncolytic viruses: current challenges and future directions.Vesiculovirus neutralization by natural IgM and complement.Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.Oncolytic Viral Therapy for Mesothelioma.Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

P2860

Q21134124-C4CC3F8C-058A-43F9-B61F-2032F5FE799E Q26859879-0F4D5903-2A62-4244-99E0-F93EA96E6F36 Q26999406-B949D969-89AB-4E04-9FD5-9E1406FB763E Q27021951-721A7A4F-39EA-4319-B0D4-DDA7F84565BA Q28072097-34D45D46-D83E-486C-90B6-88D57AC76554 Q30422218-C5DEFC05-64E1-4F72-9110-98E1DD4E21BA Q33434692-AC5897D2-8B17-483F-B114-2016D54D65C8 Q33820717-9BBD660A-30CF-4AAA-8643-61D5E2C5B260 Q34382986-EC07F617-EDC3-4C78-BA12-EDD05E553ED3 Q34420326-B561021B-470A-455E-A492-A22B1E0DEE08 Q34757186-7751C6D4-355C-4136-A206-C602732CA97C Q35285887-8123CD6F-1F0B-48C4-8E79-23188918F010 Q35612571-8C2BCC82-7178-4998-B3E5-DF744A7D6AF5 Q35666025-FC57D87A-AA7A-4C70-BD00-F45997354096 Q35785494-801098FF-DEE8-4E87-B0FC-BD5133B3E8B5 Q35818876-CEDBCEB2-0B4E-4823-9D62-49EAB370509B Q36413058-2C35D51C-B3FC-416C-A3C5-0CF9131ED5AC Q36892290-29D87D03-9D66-4DE9-995D-3240CF784D69 Q37261017-517F43A6-47CC-4E6E-BA45-06839A73FCEC Q37388411-F0666D52-4A36-482B-A2C4-6E5588FE55BB Q37494004-0004C77E-B0DC-4CF7-BA93-745BE5F62E6E Q37810599-1159488C-B43A-49C1-B121-8563AEC61BC8 Q37865172-AD448D3A-2D2B-4EEB-BEA6-D3E0D4136C34 Q38025263-4FC67CBD-BE3F-4740-8713-FE2C12EDD497 Q38025696-C31143C4-B14B-4C1A-B856-16440751B9A9 Q38212137-08AC3090-1181-4EB5-9165-409C44ADA46A Q38218674-A751772D-B750-4B50-BC32-6E05D29B196B Q38764947-36CCC6CA-BA95-4AE7-AAE1-305410FAB78F Q38808823-3757DA8B-3866-42B3-820A-DFF035B62EB5 Q38924531-377A60D3-16B0-4F3B-BCF8-A9EAEDAE1D46 Q39013686-F0657983-3AB9-4B2E-9A6D-F3306B813A1C Q39127778-16CCCA77-F9CE-4DE6-B07A-1DA39BD4AE88 Q39327842-2344923A-9DEE-4DC7-A261-C9C0545B1261 Q39556062-27AB76EC-41D5-44B5-B4BB-BA8D791F8A97 Q39572142-F81780DB-0181-420F-B3F8-18A286E5127A Q39633869-50964DEA-9202-4CB7-9219-C37875E74B74 Q39788723-1E3D4EC6-7BA5-4CF5-92EF-54DD31164EB9 Q40051845-1750A5D6-F5E4-4459-9791-6D8F4781474E Q42144185-8F3BBA31-CC58-4CD5-86AC-4C2E8431AD40 Q42412637-D30149BA-58A2-4C1C-B55F-479B18386C10

P2860

Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

http://www.wikidata.org/entity/Q33930081

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Systemic therapy of disseminat ...... virus-infected cell carriers.

@ast

Systemic therapy of disseminat ...... virus-infected cell carriers.

@en

type

label

Systemic therapy of disseminat ...... virus-infected cell carriers.

@ast

Systemic therapy of disseminat ...... virus-infected cell carriers.

@en

prefLabel

Systemic therapy of disseminat ...... virus-infected cell carriers.

@ast

Systemic therapy of disseminat ...... virus-infected cell carriers.

@en

P1433

Q33930081-03B53F49-C4D5-404F-BA46-37F4CEBC04ED

P1476

Q33930081-9DE02A64-FB06-4B86-BA57-CB82FD027FE2

P2093

Q33930081-BBD69DF1-3200-48CA-9A28-9983B9D34AB6

P2860

Q33930081-0F3D07A1-3A25-4AF0-AFB4-703BF35AFA4A

Q33930081-17A2C779-08D4-4C65-BAC2-9F50317FCB95

Q33930081-1A888503-887B-4532-A98D-CA5F8FFD6F22

Q33930081-2696F0B2-7BD0-4621-AB7D-931B5F9EC2FA

Q33930081-328A5E82-B4F3-492E-B806-81B7C20FA928

Q33930081-33F8C25E-F9B4-4D81-B66A-CF243D8591EA

Q33930081-42736C6B-6745-4747-8A60-847AD88A183A

Q33930081-465B69AB-5D2C-4FFA-8C7E-5C6C7DC27FDC

Q33930081-4A0B3E39-FB2E-444C-9799-9DEDFED705D2

Q33930081-51017B8F-573C-4FA3-A55B-5E3BAB00EC8B

P304

Q33930081-D960DE12-8057-4DB6-94E6-3C7EE81DA818

P31

Q33930081-52FF0A21-5F8A-4004-85D1-D8BF9A8D4305

P356

Q33930081-F84146CD-5418-4C0F-8035-163021D4C0A6

P433

Q33930081-D412E723-53E4-4D92-B721-3C030299AC0F

P478

Q33930081-2317A1E3-D602-4426-B064-556D95284510

P50

Q33930081-18F59A42-CDC9-4C2C-B60E-A0873978909A

Q33930081-7F60202E-F54A-4544-8F43-3DF7581FAFA8

P577

Q33930081-686644AA-FFB6-4EED-9EE7-ED550089862B

P5875

Q33930081-3B00E85C-F7FE-4EDE-985F-53AB60476C7E

P698

Q33930081-54B5AB90-D56A-4AF9-B60E-07EA2ECBFB0F

P921

Q33930081-92232544-466E-4AC3-BF86-515196D7D13C

Q33930081-C77517D6-CC5E-458A-B7FE-52C492B70365

P932

Q33930081-8E078093-96D6-4DBB-B24F-469AD2C65444

P356

P1433

Molecular Therapy

P1476

Systemic therapy of disseminat ...... virus-infected cell carriers.

@en

P2093

Chunsheng Liu

http://www.w3.org/2001/XMLSchema#string

P2860

A highly sensitive assay for monitoring the secretory pathway and ER stress.

Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.

Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.

Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo

Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus.

Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging.

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Plasma-cell homing.

Chemokines in multiple myeloma

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

P304

1155-1164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.43

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Stephen J Russell

P577

2010-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42109406

http://www.w3.org/2001/XMLSchema#string

P698

20234340

http://www.w3.org/2001/XMLSchema#string

P921

P932

2889728

http://www.w3.org/2001/XMLSchema#string